Company Description
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.
The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Randy D. Milby MBA |
Contact Details
Address: 1200 Route 22 East Bridgewater, New Jersey United States | |
| Website | https://www.tharimmune.com |
Stock Details
| Ticker Symbol | THAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001861657 |
| CUSIP Number | n/a |
| ISIN Number | US4327052001 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Randy D. Milby MBA | President, Chairman & Chief Executive Officer |
| Sireesh Appajosyula Pharm.D. | Chief Operating Officer & Director |
| Thomas P. Hess CPA, MBA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 3 | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 4 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Oct 10, 2024 | 4 | Filing |
| Oct 09, 2024 | 4/A | [Amend] Filing |
| Oct 08, 2024 | 4 | Filing |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 8-K | Current Report |